Skip to content

Understanding the Cost-Effectiveness of COVID-19 Vaccination in Nigeria

Benjamin Uzochukwu, Chinyere Okeke, Sergio Torres-Rueda, Carl Pearson, Eleanor Bergren, Anthony McDonnell, Anna Vassall, Mark Jit, Francis Ruiz
 
Researchers from the Health Policy Research Group (Prof Benjamin Uzochukwu and Dr Chinyere Okeke) were part of a project that sought to understand the cost-effectiveness of COVID-19 vaccination in terms of procurement and administration. This was documented by the Centre for Global Development (CDG), presenting useful information in scaling up campaigns against COVID-19 and improving responses to future pandemics in Nigeria.
 
Indeed, COVID-19 has disrupted health systems across the globe. Nigeria reported its first COVID-19 case in February 2020, and, since then, the government has rolled out four vaccines to help control the pandemic—Moderna, Oxford-Astra Zeneca (AZ), Johnson & Johnson (J&J) and Pfizer-BioNTech.
 
Nigeria set an ambitious goal of vaccinating 40 percent of its over 200 million people before the end of 2021, and 70 percent by the end of 2022. The vaccine rollout was organised into four phases, as shown in table 1. Access to vaccines in Nigeria has been limited, however, and vaccine hesitancy has further slowed down deployment. There is also limited evidence on the comparative clinical and cost-effectiveness of COVID-19 interventions—including vaccination—in the Nigerian context specifically.
 
Health Technology Assessment (HTA) is a framework for assessing whether healthcare interventions—including vaccines—offer good value for money and take into account a wide range of considerations. The University of Nigeria Nsukka, the London School of Hygiene and Tropical Medicine, the Center for Global Development, and the Africa Centres for Disease Control collaborated to support key national and regional stakeholders in evaluating the cost-effectiveness of Nigeria’s COVID-19 vaccine strategies using an HTA framework.
 
KEY POLICY QUESTIONS
  1. Which COVID-19 vaccines should Nigeria purchase and how much would it cost?
  2. How should these vaccines be distributed?
  3. What age groups should be targeted?
 
To read more click here

Powered by WordPress